EHA Grants Hall of Fame

Quality of Life and Symptoms

The goals of the SWG are:

To promote the evaluation of patient-reported outcomes (PROs) in hematology in daily clinical practice and in clinical trials.

Position of EHA on the Harmonization of Training and Education in Europe

 

The challenge
Education and training are largely national competencies.

A new targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukemia

Patients with chronic lymphocytic leukemia (CLL) that has recurred or isn’t responding to standard treatment need new therapies. A new combination of two targeted therapies is showing potential to eliminate CLL in these circumstances.

Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma – an open-label, dose escalation followed by open-label extension in a single-arm phase I/II study

Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.

Highlights of Past EHA - Cairo 2017

Dates: September 14 - 15, 2017
Location: Cairo, Egypt
Chairs: 
Prof Azza Kamel, Secretary General, Egyptian Society of Hematology and Research (ESHR)
Prof Amal El-Beshlawy, Vice President, Egyptian Society of Hematology and Research (ESHR)
Prof John Gribben, President elect, European Hematology Association (EHA)
Prof Mohamad Qari, President, Pan…